Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.51 |
| ▸ | ALPI | P09923 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | XIAP | P98170 | 1/20 | 0.51 |
| ▸ | TPH1 | P17752 | 7/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.44 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2312120 | 0.83 | CYP3A4 (0.43) | SLC7A5PKMPTGS1TPH1PTPN1 | |
| SCHEMBL2312128 | 0.83 | CYP3A4 (0.43) | SLC7A5PKMPTGS1TPH1PTPN1 | |
| Hydrochloric Acid SCHEMBL6480180 | 0.82 | CYSLTR1 (0.42) | CYSLTR2CYSLTR1ALOX5FFAR1AKR1B1 | |
| Hydrochloric Acid SCHEMBL6480174 | 0.82 | CYSLTR1 (0.42) | CYSLTR2CYSLTR1ALOX5FFAR1AKR1B1 | |
| SCHEMBL2307802 | 0.81 | SLC7A5 (0.43) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL2307814 | 0.81 | SLC7A5 (0.43) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL2309041 | 0.80 | TPH1 (0.45) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL2309034 | 0.80 | TPH1 (0.45) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL29584001 | 0.79 | SLC7A5 (0.70) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL515521 | 0.79 | SLC7A5 (0.70) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288549-B2 | Glycine B antagonist | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-10-16 | — | — | US | disclosed |
| US-20110190342-A1 | GLYCINE B ANTAGONIST | HENRICH MARKUS | 2011-08-04 | — | — | US | disclosed |
| EP-2350014-A1 | GLYCINE B ANTAGONISTS | Merz Pharma GmbH & Co. KGaA (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010037533-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA (DE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190342-A1 | GLYCINE B ANTAGONIST | GRIN2B, GLRB, GRIN2A | SLC7A5 159/4885ALPI 4486/4885PKM 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.